Clinical Trial Update: RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD [Phase 2]

View source ↗

Summary

Phase 2 GUARD trial evaluating RTA 408 ophthalmic suspension to prevent corneal endothelial cell loss after cataract surgery; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cataract

Drugs mentioned

• RTA 408 ophthalmic suspension (omaveloxolone)

Snippet

Sponsor: Biogen | Conditions: Corneal Endothelial Cell Loss, Ocular Pain | Phase 2 | Status: COMPLETED | Results posted: 2023-05-26